智通财经APP获悉，银诺医药-B(02591)再涨近7%，四个交易日股价累计涨超50%。截至发稿，涨6.79%，报44.68港元，成交额3536.66万港元。
消息面上，11月21日，恒生指数系列季度检讨结果出炉，其中，银诺医药获纳入恒生综合指数成份股，变动将于2025年12月8日起生效。据中金预测，银诺医药等符合港股通纳入范围。
据悉，银诺医药是一家专注于代谢性疾病领域的生物医药公司，目前拥有多项针对糖尿病、肥胖和非酒精性脂肪性肝炎等适应症的创新药物研发管线，全部为自主研发，具备全球知识产权，覆盖全球研发与市场布局。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.